Phase IV non-inferiority trials and additional claims of benefit. - Wikidata - awgldk - TriplyDB

Phase IV non-inferiority trials and additional claims of benefit.

Phase IV non-inferiority trials and additional claims of benefit.

http://www.wikidata.org/entity/Q34747480

about

The fiduciary obligation of the physician-researcher in phase IV trials.Assessing additional benefit in noninferiority trials.Design and Interpretation of Noninferiority Trials

P2860

Q37580151-A28FC647-CB5D-4609-8CF2-C55AA0C34683 Q48263630-43BF760F-089E-44F3-AC9D-63045370DF3C Q58433662-C92C2879-444B-496A-A8A4-BA4BC2AF65B8

P2860

Phase IV non-inferiority trials and additional claims of benefit.

http://www.wikidata.org/entity/Q34747480

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase IV non-inferiority trials and additional claims of benefit.

@ast

Phase IV non-inferiority trials and additional claims of benefit.

@en

Phase IV non-inferiority trials and additional claims of benefit.

@nl

type

label

Phase IV non-inferiority trials and additional claims of benefit.

@ast

Phase IV non-inferiority trials and additional claims of benefit.

@en

Phase IV non-inferiority trials and additional claims of benefit.

@nl

prefLabel

Phase IV non-inferiority trials and additional claims of benefit.

@ast

Phase IV non-inferiority trials and additional claims of benefit.

@en

Phase IV non-inferiority trials and additional claims of benefit.

@nl

P1433

Q34747480-DCF34EE2-F15B-4291-88F0-1F7894A0AEB5

P1476

Q34747480-F2814C9E-4C26-4C6F-BC79-0A33CB11AF5E

P2093

Q34747480-025D805D-C818-4B5E-9502-85D778928C09

Q34747480-1E9854AF-61A8-4326-BA4C-4616A5FDA0EC

Q34747480-27089031-2D6A-4F21-AE6E-DCD63F99D08A

Q34747480-2E7F72E6-DC5F-448B-8482-2B4B9C258BDA

Q34747480-85BE5512-BA41-4EC1-B583-317CA2413309

Q34747480-A6886C62-1B3D-4C65-9F5A-8414DC242C12

Q34747480-AC949176-9CDC-498F-BB44-E6BEEDCDA2FC

Q34747480-EB695628-F70A-4008-B958-7E945A1E8439

P2860

Q34747480-1F5E1AF2-2B62-416F-B72B-3CFD44753327

Q34747480-3DB17603-074E-4D4B-97F8-2F9360A8AEFF

Q34747480-6DACD523-8E50-4F56-AE30-37C44E4474BF

Q34747480-CCB85D0E-76DB-4FDE-9794-CF2DF48C5E54

Q34747480-E106495E-8102-44CD-9E9B-6F9175FB50D6

Q34747480-F64AD861-905A-4EE3-9743-F3DA72F435CF

P2888

Q34747480-C6471D82-10E0-456B-B9F8-7EE210431096

P304

Q34747480-4B24927B-2EEF-4D2C-AA1B-7A4A12994D91

P31

Q34747480-E1C2DF33-39BF-4539-8F93-0494202FAEDC

P356

Q34747480-00EE68A2-5F9E-4B71-80C7-CE6E0FEE6210

P478

Q34747480-EC021FDB-BAAB-46FC-A9A8-00269D16004A

P50

Q34747480-6D810D53-0470-49AE-85C5-1A085250B345

Q34747480-BBC2F1DD-BEE1-444C-B88C-71DC39BD3F8C

P577

Q34747480-E9077ADA-1094-4D80-9317-CA43996850C0

P5875

Q34747480-E63EA604-BAF2-4C96-9816-4D254572244E

P6179

Q34747480-11D405C6-FDE6-4068-8AA9-4D95FA714789

P698

Q34747480-C5FA6A96-719A-4CCA-8000-11E0511F8A06

P921

Q34747480-BDD6DD13-B1FA-4C59-8DCD-0AC9A34E2D10

P932

Q34747480-58051722-2834-40AC-884C-C412821E9898

P356

1471-2288-13-70

P1433

BMC Medical Research Methodology

P1476

Phase IV non-inferiority trials and additional claims of benefit.

@en

P2093

Anthonius de Boer

http://www.w3.org/2001/XMLSchema#string

Arno W Hoes

http://www.w3.org/2001/XMLSchema#string

Ghislaine J M W van Thiel

http://www.w3.org/2001/XMLSchema#string

Grace Wangge

http://www.w3.org/2001/XMLSchema#string

Jan A M Raaijmakers

http://www.w3.org/2001/XMLSchema#string

Mirjam J Knol

http://www.w3.org/2001/XMLSchema#string

Olaf H Klungel

http://www.w3.org/2001/XMLSchema#string

Rosemarie D L C Bernabe

http://www.w3.org/2001/XMLSchema#string

P2860

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Interpretation and inference in noninferiority randomized controlled trials in drug research.

Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.

Equipoise should be amended, not abandoned.

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

P2888

1471-2288-13-70

P304

70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2288-13-70

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Johannes van Delden

P577

2013-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236975874

http://www.w3.org/2001/XMLSchema#string

P6179

1013675538

http://www.w3.org/2001/XMLSchema#string

P698

23721202

http://www.w3.org/2001/XMLSchema#string

P921

phase IV clinical trial

P932

3679839

http://www.w3.org/2001/XMLSchema#string